Pharma's Almanac

In this roundtable from the close of 2023, we asked a panel of industry experts about the year's defining event in pharma/biopharma. Read the roundtable here: https://lnkd.in/da3fd6kj Our roundtable includes contributors from Be The Match BioTherapies, GBI Biomanufacturing, Lonza, Samsung Biologics, Tedor Pharma Services, Addimmune™, ADVI Health, Agilent Technologies, AnaptysBio, Astrea Bioseparations, Atomic AI, BioCina, BIOSENIC S.A., Bruker BioSpin, Cellares, CellProthera SAS, Click Therapeutics, Inc., CoRegen Inc., CRB, Cyclacel Pharmaceuticals, Inc., eClinical Solutions, Ellab - Validation & Monitoring Solutions, Elicio Therapeutics, Elixirgen Therapeutics, Inc., Enthought, Epocrates (use this one), Evonik, F2G, Faeth Therapeutics, HDT Bio, KBio, Likarda, LGM Pharma, Medicus Pharma Ltd., Mission Bio, MOBILion Systems, Inc., Newfront, Norstella, Nucleus RadioPharma, OM1, Inc., ... (cont.)

Discover innovative solutions advancing women's health beyond traditional boundaries. Fab Biopharma was founded to address under-researched conditions that disporportionately affect women. In this exclusive Q&A, Chia Chia Sun and Gardiner Smith, two of Fab Biopharma's founders, dive into the company's mission, vision, and unique expertise driving the development of effective treatments for women. Read the full article here: https://lnkd.in/em8aUq7f #WomenHealth #Biopharma #CDMO #CDMOExcellence

Discover the pivotal role of partnerships between global drug developers and CDMOs in driving project success. In this exclusive article, JC Ryan Lee, Senior Director of Sales Operations at Samsung Biologics, shares insights on fostering enduring, trust-driven collaborations. These partnerships empower CDMOs to enhance service excellence and advance their partners' business visions — and missions for patient care. Read the case study here: https://lnkd.in/epfmzFm5 #CDMOExcellence #Pharma #Partnership

Touchlight's enzymatically amplified dbDNA™ (doggybone DNA) tackles major hurdles in adeno-associated viral (AAV) vector manufacturing. In this exclusive article, Tom Merritt, Associate Director of dbDNA Applications for Viral Vectors Touchlight, shares how how Touchlight's innovation lowers the cost of AAV-based therapeutics and accelerates development pathways. Read the full article here: https://lnkd.in/eS3Nemp2 #AAV #Biotech #DNA #CDMO

Celebrating over 15 years of excellence, Coriolis Pharma stands out for its scientific expertise and commitment to accelerate client drug development timelines. In this exclusive Q&A, Silvia Steyrer-Gruber, Chief Executive Officer of Coriolis Pharma, shares insights into the company's pivotal role in the contract research and development sector. Read the full article here: https://lnkd.in/ewieACdj #CDMOExcellence #Pharma #DrugDevelopment

CD3, a protein complex and T cell co-receptor, serves as the primary target for bispecific antibodies. Bispecifics are attracting significant attention and investment due to their precise targeting capabilities. How do you foresee the evolution of bispecifics over time? #biopharma #bispecific #tcell #immunooncology Nice Insight

In case you missed it:this new Pharma's Almanac roundtable, a panel of industry experts weighs in on the most impactful investment trends influencing pharma and biopharma. This roundtable features contributors from: Alconox Inc., TriRx Pharmaceutical Services, LLC, Sonata Therapeutics, Flagship Pioneering, GBI Biomanufacturing, Fab Biopharma, Quotient Sciences, Mikart, LLC, Oxford Biomedica, PCI Pharma Services, Samsung Biologics, Simtra BioPharma Solutions, Cambrex, Astrea Bioseparations, N4 Pharma Plc, Lonza, SK pharmteco, Center for Breakthrough Medicines, Epocrates Inc, Thermo Fisher Scientific, OM1, Inc., Bruker BioSpin, MilliporeSigma, Certara, Seer, eClinical Solutions, Spinogenix, Inc., ProPharma, ScaleReady, REITHERA, eXmoor Pharma, NextCell Pharma AB, OrganoBiotech, Inc., and Catalent Pharma Solutions See the full roundtable here: https://lnkd.in/g3C3Dj7B

In case you missed it: in this Q2 roundtable on Pharma's Almanac, SMEs from across the industry discuss how technology providers can help transition to more digitally connected operations. Our panel includes experts from TriRx Pharmaceutical Services, LLC, GBI Biomanufacturing, Quotient Sciences, Nu-Tek BioSciences, Mikart, LLC, Oxford Biomedica, PCI Pharma Services, Samsung Biologics, SCIEX, Cytiva, Cambrex, Astrea Bioseparations, BioIVT, LabVantage Solutions, Inc, Lonza, SK pharmteco, Thermo Fisher Scientific, OM1, Inc., Bruker BioSpin, MilliporeSigma, Certara, eClinical Solutions, ProPharma, ScaleReady, Green Elephant Biotech, Likarda, Terumo Blood and Cell Technologies, NextCell Pharma AB, VIVEbiotech, OrganoBiotech, Inc., and IDBS. Read the full roundtable here: https://lnkd.in/gxZTgyu5

Discover the pivotal role of partnerships between global drug developers and CDMOs in driving project success. In this exclusive article, JC Ryan Lee, Senior Director of Sales Operations at Samsung Biologics, shares insights on fostering enduring, trust-driven collaborations. These partnerships empower CDMOs to enhance service excellence and advance their partners' business visions — and missions for patient care. Read the case study here: https://lnkd.in/epfmzFm5 #CDMOExcellence #Pharma #Partnership

Monoclonal antibodies (mAbs) dominated global biopharma sales at $204 billion in 2023, comprising 80% of the market. While demand remains strong, the emergence of next-generation therapeutics like bispecific antibodies raises questions about their future dominance. For more insights, visit Pharma's Almanac (https://lnkd.in/e77g8NWx) and our colleagues at Nice Insight (https://lnkd.in/ebvt3-WY) #biopharma #antibody #biologics #mab #monoclonalantibody #bispecific